<p>|Recommendation|Level of evidenceâ€ |
|---|---|
|In adult patients with active PsA despite treatment with an IL-17i biologic monotherapy,| |
|1. Switch to a TNFi biologic over switching to an IL-12/23i biologic (PICO 39)|Very low|
|Conditional recommendation based on very-low-quality evidence; may consider switching to IL-12/23i if the patient has contraindications to TNFi biologics, including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease, or prefers less frequent drug administration.| |
|2. Switch to a TNFi biologic over switching to a different IL-17i biologic (PICO 42)|Very low|